Loading organizations...
§ Venture Capital · USA, Europe
Venture capital firm investing in early-stage companies in human and animal health, focused on life sciences and health technologies.
Digitalis Ventures is a New York-based venture capital firm that invests in early-stage companies addressing unmet clinical and operational needs across the human and animal health sectors. The firm manages an active portfolio of over 50 companies and has completed 77 total investments, maintaining a historical average check size of $6.1 million and a maximum check size of $260 million. Operating specialized investment vehicles like its Companion Fund, the firm targets biotechnology, digital therapeutics, and healthcare infrastructure solutions, recently participating in a $107 million Series B and a separate $25 million early-stage funding round. Its current investment portfolio includes emerging life sciences startups such as Expressable, Elegen, and Alterome Therapeutics, alongside notable historical exits to major pharmaceutical corporations like Zoetis and Roche. Digitalis Ventures was established in 2016 by founder and managing partner Geoffrey Smith.
Key people at Digitalis Ventures.
Key people at Digitalis Ventures.
Digitalis Ventures is a New York-based venture capital firm specializing in early-stage investments primarily within healthcare, biotechnology, and animal health sectors. Their mission centers on investing in innovative solutions that address unmet needs in human and animal health, leveraging deep technical, financial, and domain expertise to help startups scale and create lasting impact. The firm supports companies developing breakthrough therapeutics, diagnostics, and technology-enabled healthcare solutions that improve access, outcomes, and reduce costs. Digitalis Ventures also operates a dedicated Companion Fund focused on advancing animal health technologies, reflecting a broad commitment to health innovation across species[1][2][3][4].
Founded in 2016 by Geoffrey W. Smith, Digitalis Ventures draws inspiration from a legacy of scientific innovation and human connection rooted in Smith’s family history in medicine and research. The firm has evolved to combine venture capital with applied research and nonprofit initiatives under the Digitalis Group umbrella, including Digitalis Research and Digitalis Commons, which focus on health technology innovation and public-interest solutions. Key partners such as Amit Bansal and Drew Taylor bring extensive experience in venture investing and health technologies, helping the firm lead investment rounds and provide strategic guidance to portfolio companies[2][3][6].
Digitalis Ventures rides the growing trend of integrating biotechnology with digital health and animal health technologies, sectors experiencing rapid innovation driven by advances in science and technology. The timing is favorable due to increasing demand for improved healthcare access, cost reduction, and personalized medicine solutions. Their focus on early-stage companies positions them to influence the ecosystem by nurturing disruptive innovations that can transform healthcare delivery and outcomes. Their multidisciplinary approach and involvement in both human and animal health reflect a holistic view of health innovation, contributing to a broader ecosystem that spans therapeutics, diagnostics, and technology-enabled care[2][3][4].
Looking ahead, Digitalis Ventures is poised to continue expanding its influence by investing in cutting-edge biotech and health technology startups that address critical unmet needs. Trends such as AI-driven diagnostics, personalized medicine, and integrated animal-human health solutions will likely shape their investment focus. Their integrated model combining venture capital with research and nonprofit initiatives may increasingly serve as a blueprint for impact-driven health investing. As healthcare continues to evolve rapidly, Digitalis Ventures’ role in engineering health solutions positions them to be a key player in shaping the future of both human and animal health innovation[3][4].
Digitalis Ventures has more than 26 tracked investments across 23 companies. The latest tracked deal is $107.0M Series B in EpiBiologics in January 2026.